Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia

NCT01725217 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01725217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01725217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2012
Completion date
March 31, 2013
Enrollment
198 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease